# About This Ipamorelin Evidence Review

> About Reviews Ipamorelin — an independent editorial project summarizing the peer-reviewed Ipamorelin literature through its gut-motility and appetite lens. Not a clinic.

An independent editorial reading of the published research, led by the ghrelin-receptor lens.

## An editorial reading, not a clinic

Reviews Ipamorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on Ipamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word "reviews" in our name means exactly one thing: we review the published *evidence*. We do not review vendors, products, or sellers, and nothing here is an endorsement of any supplier. When we say a finding is "reviewed," we mean it has been read against its source study and weighed for what it does and does not support.

## Why we lead with the gut

Most writing about ipamorelin leads with growth hormone and muscle. We lead with the gut and appetite, because that is where the molecule's biology is most revealing. Ipamorelin acts on the ghrelin receptor — the same receptor the body's hunger hormone uses — and that receptor sits in the stomach and the brain's appetite centers as much as in the pituitary. Reading ipamorelin through motility and hunger surfaces both its strongest mechanistic rationale and its most honest limitation: a clinically advanced drug class, and a single ipamorelin trial that did not succeed.

We weigh evidence rather than promote it. Where the data are strong — selectivity, pharmacokinetics — we say so plainly. Where they are thin, negative, or absent, we say that too. The failed Phase 2 trial is not buried here; it is central.

## How we handle the evidence

Every quantitative claim on this site is tied to a numbered citation with a DOI, PMID, or trial identifier. We distinguish carefully between what controlled human trials show, what animal and cell studies show, and what research-use communities report — and we label community reports as anecdotal, never as findings. We describe doses only as they appear in published studies, in the third person, and we never present a human dosing recommendation. Ipamorelin is not approved for human use by any regulatory authority, and we treat it strictly as a subject of research.

---

A long-form evidence review of the ipamorelin record read through its gut and appetite biology — the founding selectivity data weighed against the single failed human trial, and the word 'reviews' meaning only that the literature is appraised, never that a clinic, a vendor, or a prescription stands behind it.